DS 1471
Alternative Names: DS-1471; DS-1471aLatest Information Update: 12 Jan 2024
At a glance
- Originator Daiichi Sankyo Company
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Membrane-associated matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC - 2023)
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC - 2023)
- 04 Aug 2023 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (IV) (NCT06074705)